Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Preclinical Studies Yield New Pathway Clues in Medulloblastoma

August 28th 2013

Since the mid-1970s, Rakesh K. Jain, PhD, has pursued an interest in the role that tumor microenvironment plays in drug delivery and efficacy.

Dr. Parsa on the Administration of the G-200 Vaccine in GBM

August 21st 2013

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Dr. Roth on the Treatment of Cancers With Bevacizumab

August 15th 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.

Dr. Lesser on Armodafinil for Radiation-Induced Fatigue

August 1st 2013

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for brain radiation-induced fatigue.

Dr. Parsa on a Trial Analyzing G-200 for Glioblastoma

July 2nd 2013

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Dr. Lesser on the Background of the RTOG 0424 Study

June 17th 2013

Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.

Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses

June 3rd 2013

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

First-Line Bevacizumab Does Not Improve Survival in Glioblastoma

June 2nd 2013

Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.

New Mechanism of Resistance Identified in Brain Tumors

April 17th 2013

Researchers have identified a mechanism that explains why patients with glioblastoma have not had successful outcomes when treated with inhibitors of mTOR despite the fact that it is overexpressed in approximately 90% of cases.

Notch Holds Promise, but Presents Obstacles as Cancer Target

March 1st 2013

Benjamin W. Purow, MD, a researcher whose focus is on glioblastomas, discusses the Notch pathway and the development of Notch-targeted anticancer agents.

Bevacizumab Results Offer Support for Upfront Therapy

February 5th 2013

Several recent clinical trials have yielded positive data that may open up new treatment options for patients with glioblastoma.

Meningioma May Be Tied to Dental X-Rays

November 29th 2012

New data suggest that dental x-rays obtained frequently at a young age may boost the risk of intracranial meningioma.

Chemoradiation Established as New Standard in Glioma Subtypes

August 14th 2012

A study that unfolded over 17 years has established combination chemotherapy after radiotherapy as a new standard of care for patients with anaplastic oligodendroglial tumors that contain 1p/19q chromosomal co-deletions.

Unexpected Mutations Doom Therapy for Glioblastoma

June 25th 2012

Unexpected target mutations likely doomed a proven therapeutic approach to lung cancer in a test against glioblastoma.

Surviving Brain Cancer During Pregnancy

April 9th 2012

Antonia Reyes was 39 years old and 18 weeks pregnant when an MRI revealed an apparent glioma in the right temporal-parietal lobe region.

Clinical Management of Primary Brain Tumors

January 6th 2012

At NCONN 2011, Sean Grimm, MD, discussed the management of Glioblastoma multiforme, the most common malignant primary brain tumor.

Dr. Grimm on the Brain Cancer Predictive Marker MGMT

November 4th 2011

Dr. Sean Grimm from Northwestern University, Feinberg School of Medicine on MGMT as a Predictive Marker in Brain Cancer

Valproic Acid May Prolong Survival in Glioblastoma

November 1st 2011

New data suggest that patients with glioblastoma who are treated with valproic acid, an antiepileptic drug (AED), are likely to outlive patients who receive another type of AED or no AED at all.

Dr. Grimm Discusses Primary Brain Cancer Risk Factors

October 31st 2011

Dr. Grimm from Northwestern University, Feinberg School of Medicine Discusses Brain Cancer Risk Factors

ASCO Highlights: Trials in Progress

August 23rd 2011

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.